{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-266916","form_type":"8-K","ticker":"TYRA","cik":"0001863127","company_name":"Tyra Biosciences, Inc.","filed_at":"2025-11-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.865749+00:00","generated_at":"2026-05-17T00:24:43.968990+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Tyra Biosciences Q3 net loss $29.9M; cash $274.9M; dabogratinib trials on track","bullets":["Cash, equivalents, and marketable securities of $274.9M as of Sep 30, 2025; runway through at least 2027.","Q3 net loss $29.9M vs $24.0M in Q3 2024; R&D spend $25.5M (up from $22.7M) on trial initiations.","First patients dosed in Phase 2 achondroplasia (BEACH301) and NMIBC (SURF302) studies; interim data expected 2026.","FDA cleared IND for dabogratinib in low-grade upper tract urothelial carcinoma (SURF303); Phase 2 start in 2026.","Upcoming milestones: SURF302 3-month CR data in 1H 2026; BEACH301 safety sentinel results in 2H 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-266916","json":"https://secwatch.observer/filing/0001193125-25-266916.json","markdown":"https://secwatch.observer/filing/0001193125-25-266916.md","text":"https://secwatch.observer/filing/0001193125-25-266916.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1863127/000119312525266916/0001193125-25-266916-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1863127/000119312525266916/tyra-20251105.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T00:24:43.968990+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}